Chemicals competition mars financial picture for Merck KGaA

8 March 2018

Shares in Darmstadt, Germany-based Merck KGaA (MRK: DE) slumped almost 5% by mid-afternoon today, as the German chemicals and pharmaceuticals manufacturer revealed a drop in earnings due to a “difficult foreign exchange environment,” and Chinese competition in its liquid crystals business.

The picture was more positive on the pharmaceuticals side, with the firm’s healthcare and life science businesses driving sales growth of 2%.

However, currency headwinds would likely lead to a drop in 2018 adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), the firm said, with foreign exchange rates likely to create a 4%-6% negative impact.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK